Biotech Values

[Whalatane]

Dew wrote a post about NVO's CKD trial with Ozempic .
You responded by lumping this trial and its potential impact on those with CKD ...with your over all view on how Ozempic is being used .
Perhaps you could address the intro of Dew's piece ...the affect on dialysis and med tech stocks....because for those in stage 4 CKD, this trials results may have a significant impact on their life expectancy and their need for dialysis ( and by extension on the companies that sell meds or med tech for this population )
We don't know how much Ozempic slows decline in eGFR ( kidney function ) yet in this population . But since the trial was stopped 1 yr early for efficacy I'll assume if must be significant .
Kiwi